Biotech Turns To Private Investors
This article was originally published in Start Up
Executive Summary
As the public market for biotech issues has dried up, it's not surprising that public biotechs would rely more heavily on institutional investors for financing. Notable, however, is that so far this year, publicly traded biotechs have actually raised more cash privately than they have in follow-on public offerings.